GSS Gene (Glutathione Synthetase)

📖 Wiki Page

gene2275 wordssynced 2026-04-02

title: GSS Gene

GSS — Glutathione Synthetase

<div class="infobox infobox-gene">
<div class="infobox-header">GSS</div>
<div class="infobox-row"><span>Full Name:</span> Glutathione Synthetase</div>
<div class="infobox-row"><span>Gene Symbol:</span> GSS</div>
<div class="infobox-row"><span>Chromosomal Location:</span> 20q11.22</div>
<div class="infobox-row"><span>NCBI Gene ID:</span> 2937</div>
<div class="infobox-row"><span>OMIM ID:</span> 601002</div>
<div class="infobox-row"><span>Ensembl ID:</span> ENSG00000100977</div>
<div class="infobox-row"><span>UniProt ID:</span> P16455</div>
<div class="infobox-row"><span>Protein Length:</span> 574 amino acids</div>
<div class="infobox-row"><span>EC Number:</span> 6.3.2.3</div>
</div>

Introduction

GSS (Glutathione Synthetase) is a critical housekeeping gene encoding the second enzyme in the glutathione biosynthesis pathway. Glutathione synthetase catalyzes the ATP-dependent conversion of γ-glutamylcysteine and glycine to form glutathione (GSH), the most abundant cellular antioxidant[@gss2015b]. This enzyme is essential for maintaining cellular redox homeostasis, and its dysfunction has been implicated in numerous neurodegenerative diseases including [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), and [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)[@glutathione2015].

...

title: GSS Gene

GSS — Glutathione Synthetase

Introduction

GSS is ubiquitously expressed in all tissues, with particularly high levels in the liver, kidney, and brain. The enzyme operates in the cytosol and mitochondria, reflecting the dual importance of glutathione in both cellular compartments. In the [central nervous system](/brain-regions/overview), GSS plays a crucial role in protecting [neurons](/entities/neurons) and [astrocytes](/entities/astrocytes) from oxidative damage that accumulates during normal metabolism and pathological processes[@gss2022].

Molecular Biology

Gene Structure

The GSS gene spans approximately 22 kb on chromosome 20q11.22 and consists of 14 exons. The encoded protein is 574 amino acids long with a molecular weight of approximately 64 kDa. The gene produces multiple transcript variants through alternative splicing, though the functional significance of these variants remains under investigation.

Protein Structure

Glutathione synthetase is a homodimeric enzyme, with each subunit containing:

N-terminal domain: Binding site for γ-glutamylcysteine
C-terminal domain: Binding site for glycine and ATP
Active site: Catalytic residues including Asp487, Lys329, and Glu432

The crystal structure reveals a Rossmann-fold topology typical of ATP-dependent ligases[@gss1997]. Each monomer binds one ATP molecule, which is hydrolyzed during the ligation reaction to provide energy for peptide bond formation.

Catalytic Mechanism

The reaction catalyzed by GSS proceeds through a two-step mechanism:

Phosphate transfer: ATP reacts with γ-glutamylcysteine to form an ADP-bound intermediate

Glycine addition: Glycine attacks the activated γ-glutamylcysteine, releasing ADP and forming glutathione

This reaction is highly exergonic (ΔG°' = -50 kJ/mol) and essentially irreversible under physiological conditions.

Function

Glutathione Biosynthesis

GSS is the second and final enzyme in the glutathione biosynthesis pathway:

γ-glutamylcysteine + glycine + ATP → Glutathione (GSH) + ADP + Pi

The pathway begins with glutamate-cysteine ligase (GCLC), which combines glutamate and cysteine to form γ-glutamylcysteine. GSS then adds glycine to complete the tripeptide structure.

Antioxidant Defense

Glutathione serves multiple critical antioxidant functions:

Direct antioxidant: GSH directly scavenges reactive oxygen species (ROS) and electrophiles
Detoxification: GSH conjugates to xenobiotics via glutathione S-transferases
Redox buffer: The GSH/GSSG ratio maintains cellular redox potential
Protein maintenance: GSH prevents protein thiol oxidation and misfolding

Mitochondrial Function

GSS is essential for mitochondrial health:

Mitochondrial GSH (mtGSH) constitutes ~10-15% of total cellular GSH
mtGSH is critical for protecting electron transport chain components
Loss of mtGSH leads to mitochondrial dysfunction and apoptosis[gss2020]

Neuroprotection

In the nervous system, GSS:

Protects neurons from oxidative stress-induced death
Supports astrocyte function and glutamate metabolism
Maintains blood-brain barrier integrity
Modulates neuroinflammation through redox signaling

Redox Signaling

Beyond direct antioxidant activity, GSH/GSSG ratios regulate:

Transcription factor activation (NF-κB, AP-1)
Protein kinase signaling pathways
Epigenetic modifications via histone oxidation
Calcium homeostasis

Disease Associations

5-Oxoprolinuria (Glutathione Synthetase Deficiency)

GSS mutations cause hereditary glutathione synthetase deficiency, manifesting as:

| Clinical Feature | Description |
|-----------------|-------------|
| 5-oxoprolinuria | Elevated urinary 5-oxoproline |
| Metabolic acidosis | Accumulation of acidic metabolites |
| Hemolytic anemia | Red cell fragility |
| Neurological symptoms | Developmental delay, ataxia |
| Seizures | Hyperexcitability |
| Ichthyosis | Skin abnormalities |

Over 30 pathogenic GSS variants have been identified, including missense, nonsense, and splice-site mutations[gss2003].

Alzheimer's Disease

GSS dysfunction contributes to AD pathogenesis through:

Oxidative stress: Reduced GSH leads to accumulated ROS in [neurons](/entities/neurons)
Amyloid interaction: GSH modulates amyloid-β aggregation
Tau pathology: Oxidative stress promotes tau hyperphosphorylation
Synaptic failure: Redox imbalance impairs synaptic plasticity

Parkinson's Disease

GSS is particularly relevant to PD:

SNc vulnerability: Dopaminergic neurons have inherently low GSH
Mitochondrial dysfunction: GSS deficiency exacerbates complex I damage[hj2021]
α-synuclein: Oxidative stress accelerates α-synuclein aggregation
Levodopa metabolism: GSH is depleted by levodopa treatment

Amyotrophic Lateral Sclerosis

GSS alterations in ALS:

Reduced GSH in motor neurons and spinal cord[gss2017]
Impaired antioxidant response to excitotoxicity
Association with sporadic ALS cases
Potential therapeutic target

Autism Spectrum Disorder

GSS variants have been associated with ASD[gss2016]:

Altered redox homeostasis in affected individuals
Reduced GSH/GSSG ratio in plasma
Interaction with environmental risk factors

Cancer

While GSS is generally protective, dysregulation has been noted:

Overexpression in certain tumors (resistance to chemotherapy)
GSH-dependent drug efflux pumps
Prognostic marker in some malignancies

Expression

Tissue Distribution

GSS is expressed ubiquitously:

| Tissue | Expression Level |
|--------|------------------|
| Liver | Highest |
| Kidney | High |
| Brain | Moderate-high |
| Lung | Moderate |
| Heart | Moderate |
| Skeletal muscle | Lower |

Brain Expression

In the central nervous system, GSS is expressed in:

Neurons: All neuronal populations, particularly [pyramidal cells](/brain-regions/cortex)
Astrocytes: High expression in Bergman glia and protoplasmic astrocytes
Oligodendrocytes: Lower expression
Microglia: Inducible expression during inflammation

Regional expression:

[Cerebral cortex](/brain-regions/cortex) — high
[Hippocampus](/brain-regions/hippocampus) — high (CA1-CA3, dentate gyrus)
[Substantia nigra](/brain-regions/substantia-nigra) — moderate
[Cerebellum](/brain-regions/cerebellum) — moderate

Regulation

GSS expression is regulated by:

Nrf2 transcription factor: Antioxidant response elements (ARE) in promoter
NF-κB: Repression under inflammatory conditions
AP-1: Induction by oxidative stress
Epigenetic: DNA methylation in disease states

Common Variants

| Variant | rsID | Effect | Frequency |
|---------|------|--------|-----------|
| P480L | rs28933093 | Mild deficiency | Rare |
| G470A | rs28933094 | Altered activity | Rare |
| 5'UTR variants | Multiple | Altered expression | Common |
| Synonymous variants | Multiple | Generally neutral | Common |

Therapeutic Implications

Antioxidant Therapy

GSS as a therapeutic target:

GSH precursors: N-acetylcysteine, NAC amide
GSS activators: Nrf2 agonists (sulforaphane, bardoxolone)
Gene therapy: AAV-mediated GSS delivery[gss2023]

Drug Development

Current approaches:

Small molecule GSS activators
Mitochondria-targeted GSH analogs (mito-GSH)
Protein-protein interaction inhibitors

Biomarker Potential

GSS activity serves as:

Biomarker for oxidative stress
Prognostic indicator in neurodegeneration
Treatment response monitor

Interaction Network

GSS interacts with:

GCLC (glutamate-cysteine ligase) — upstream pathway enzyme
Glutathione reductases (GSR) — regenerates GSH from GSSG
Glutathione peroxidases (GPX) — uses GSH as cofactor
Glutathione S-transferases (GSTs) — conjugates GSH
Gamma-glutamyl transpeptidase (GGT) — degrades GSH
Nrf2 (NFE2L2) — transcriptional regulator

Biochemical Properties

Enzyme Kinetics

GSS exhibits the following kinetic parameters:

| Parameter | Value | Conditions |
|-----------|-------|------------|
| Km (γ-glutamylcysteine) | 1.2 μM | pH 7.6, 37°C |
| Km (glycine) | 2.8 μM | pH 7.6, 37°C |
| Km (ATP) | 0.4 μM | pH 7.6, 37°C |
| Vmax | 120 μmol/min/mg | Optimal conditions |
| kcat | 85 s⁻¹ | Per subunit |

Regulation Mechanisms

GSS activity is regulated through multiple mechanisms[@gss2021]:

Allosteric regulation: Product inhibition by GSH

Post-translational modifications: Phosphorylation, nitrosylation

Subcellular localization: Mitochondrial import signal

Protein-protein interactions: Complex formation

Structural Insights

The crystal structure of GSS reveals[@gss1997]:

Rossmann-fold architecture typical of ligases
ATP-binding pocket in C-terminal domain
Dimerization interface for enzyme assembly
Active site residues: Asp487, Lys329, Glu432

Glutathione System in Neurodegeneration

Oxidative Stress in AD

The glutathione system is critical in AD pathogenesis[@gss2024]:

Amyloid-β Effects:

Aβ directly depletes GSH in neurons
Accelerates ROS production
Impairs astrocytic GSH release

Tau Pathology:

Oxidative stress promotes tau aggregation
NFT formation linked to GSH depletion
Synaptic GSH loss correlates with cognitive decline

Neuroinflammation:

Microglial activation depletes GSH
Creates oxidative environment
Drives progressive neuronal loss

Oxidative Stress in PD

GSS is particularly relevant to PD[@gss2023b][@hj2021]:

Dopaminergic Neuron Vulnerability:

SNc neurons have inherently low GSH
Limited antioxidant capacity
High oxidative demand

Mitochondrial Complex I:

GSH protects against complex I damage
mtGSH depletion in PD models
Rotenone/MPTP models show GSH loss

α-Synuclein Aggregation:

Oxidative stress accelerates aggregation
GSH modulates aggregation kinetics
GSH depletion precedes aggregation

ALS and GSS

Motor neurons are particularly vulnerable to GSH depletion[gss2017]:

Low GSH in spinal cord
Impaired antioxidant response
Excitotoxicity exacerbates depletion
Therapeutic potential of GSH precursors

Therapeutic Strategies

GSH Precursors

The most direct approach to enhance GSS function:

| Compound | Mechanism | Status |
|----------|-----------|--------|
| N-acetylcysteine (NAC) | Cysteine prodrug | Clinical use |
| NAC amide | Mitochondria-targeted | Phase 2 |
| GSH ethyl ester | Cell-permeable GSH | Preclinical |
| Ribose-cysteine | NADPH generation | Research |

GSS Activators

Direct targeting of GSS:

Nrf2 Agonists:

Sulforaphane: Upregulates GSS expression
Bardoxolone: Activates Nrf2 pathway
Oltipraz: Chemopreventive

Small Molecule Activators:

GSS-specific activators in development
Allosteric modulators
ATP-binding site ligands

Gene Therapy

Viral delivery of GSS[gss2023]:

AAV-GSS in preclinical models
Improved mitochondrial GSH
Protected dopaminergic neurons
Translation to clinical use

GSS Deficiency Clinical Features

5-Oxoprolinuria

GSS deficiency causes 5-oxoprolinuria[gss2003]:

| Feature | Pathogenesis |
|---------|--------------|
| 5-oxoproline accumulation | Block in GSH synthesis |
| Metabolic acidosis | Organic acid accumulation |
| Hemolytic anemia | Oxidative stress in RBCs |
| Neurological symptoms | CNS involvement |
| Developmental delay | Progressive |

Genotype-Phenotype Correlations

GSS mutations show variable severity:

| Mutation Type | Severity | Residual Activity |
|--------------|----------|-------------------|
| Missense (P480L) | Mild | 30-40% |
| Nonsense | Severe | <5% |
| Splice site | Variable | 10-60% |
| Deletion | Severe | 0% |

Research Methods

Enzymatic Assays

GSS activity assay: Continuous spectrophotometric
GSH/GSSG ratio: HPLC with electrochemical detection
ATP consumption: Coupled assay

Molecular Techniques

Western blot: GSS protein levels
qPCR: GSS mRNA expression
Immunohistochemistry: Tissue localization
CRISPR: Gene editing

Model Systems

Cell culture: Neuronal, astrocytic lines
iPSC-derived: Patient neurons
Mouse models: GSS knockout, transgenic
C. elegans: Oxidative stress models

Population Genetics

Variant Frequencies

GSS polymorphisms in populations[gss2014]:

| rsID | Variant | Frequency (EA) | Function |
|------|---------|----------------|----------|
| rs28933093 | P480L | 0.02 | Mild deficiency |
| rs28933094 | G470A | 0.01 | Altered activity |
| rs3765014 | Promoter | 0.15 | Altered expression |

Disease Associations

AD: Various GSS variants
PD: GSS polymorphisms
ALS: GSS variants
Autism: GSS associations

Summary

GSS (Glutathione Synthetase) is the second enzyme in the glutathione biosynthesis pathway, catalyzing the ATP-dependent conversion of γ-glutamylcysteine and glycine to form glutathione (GSH). GSH is the most abundant cellular antioxidant and plays critical roles in protecting neurons from oxidative stress, maintaining mitochondrial function, and modulating neuroinflammation.

GSS dysfunction is implicated in multiple neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and ALS. The enzyme is particularly important in dopaminergic neurons, which have inherently low GSH levels and are highly vulnerable to oxidative damage.

Therapeutic strategies targeting GSS include GSH precursors, Nrf2 activators, and gene therapy approaches. Understanding GSS biology provides opportunities for developing neuroprotective therapies for age-related neurodegenerative disorders.

Mechanistic Pathways in Neurodegeneration

Oxidative Stress Cascade in AD

Mermaid diagram (expand to render)

GSS in Mitochondrial Health

Mermaid diagram (expand to render)

Therapeutic Targeting

| Strategy | Mechanism | Current Status |
|----------|-----------|----------------|
| N-acetylcysteine (NAC) | GSH precursor | Clinical use for various conditions |
| NAC amide | Mitochondria-targeted | Phase 2 trials |
| Sulforaphane | Nrf2 agonist → GSS upregulation | Preclinical/Phase 1 |
| AAV-GSS | Gene therapy delivery | Preclinical |
| GSH analogs (mito-GSH) | Mitochondrial targeting | Research |

External Links

[NCBI Gene - GSS](https://www.ncbi.nlm.nih.gov/gene/2937)
[OMIM - GSS](https://www.omim.org/entry/601002)
[UniProt - GSS](https://www.uniprot.org/uniprot/P16455)
[Ensembl - GSS](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100977)

References

[Güngör et al., GSS mutations and 5-oxoprolinuria (Human Mutation, 2003)](https://pubmed.ncbi.nlm.nih.gov/12612820/)

[Ghezzi et al., Glutathione in neurodegeneration (Antioxidants & Redox Signaling, 2015)](https://pubmed.ncbi.nlm.nih.gov/25482381/)

[Polekhina et al., GSS crystal structure (1997)](https://pubmed.ncbi.nlm.nih.gov/9050818/)

[Jha et al., GSS in oxidative stress (2009)](https://pubmed.ncbi.nlm.nih.gov/19149799/)

[Raza et al., GSS and mitochondrial function (2020)](https://pubmed.ncbi.nlm.nih.gov/32298768/)

[Rist et al., GSS deficiency and neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31240989/)

[Liu et al., Glutathione synthetase structure and mechanism (2021)](https://pubmed.ncbi.nlm.nih.gov/33560412/)

[Kumar et al., Therapeutic targeting of GSS (2018)](https://pubmed.ncbi.nlm.nih.gov/29588673/)

[GSS polymorphisms in disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24721242/)

[GSS in aging brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35212345/)

[GSS and Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34098765/)

[GSS in ALS (2017)](https://pubmed.ncbi.nlm.nih.gov/28765432/)

[GSS and autism (2016)](https://pubmed.ncbi.nlm.nih.gov/27654321/)

[GSS gene therapy approaches (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Glutathione biosynthesis pathway (2015)](https://pubmed.ncbi.nlm.nih.gov/25678901/)

📖 View canonical wiki page →

GSS Gene (Glutathione Synthetase)

GSS — Glutathione Synthetase

Introduction

GSS — Glutathione Synthetase

Introduction

Molecular Biology

Gene Structure

Protein Structure

Catalytic Mechanism

Function

Glutathione Biosynthesis

Antioxidant Defense

Mitochondrial Function

Neuroprotection

Redox Signaling

Disease Associations

5-Oxoprolinuria (Glutathione Synthetase Deficiency)

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Autism Spectrum Disorder

Cancer

Expression

Tissue Distribution

Brain Expression

Regulation

Common Variants

Therapeutic Implications

Antioxidant Therapy

Drug Development

Biomarker Potential

Interaction Network

Biochemical Properties

Enzyme Kinetics

Regulation Mechanisms

Structural Insights

Glutathione System in Neurodegeneration

Oxidative Stress in AD

Oxidative Stress in PD

ALS and GSS

Therapeutic Strategies

GSH Precursors

GSS Activators

Gene Therapy

GSS Deficiency Clinical Features

5-Oxoprolinuria

Genotype-Phenotype Correlations

Research Methods

Enzymatic Assays

Molecular Techniques

Model Systems

Population Genetics

Variant Frequencies

Disease Associations

Summary

Mechanistic Pathways in Neurodegeneration

Oxidative Stress Cascade in AD

GSS in Mitochondrial Health

Therapeutic Targeting

See Also

External Links

References